CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 20 pages
Economics of Respiratory Syncytial Virus (RSV) Vaccination in All U.S. Adults≥75 years -old, and Adults aged 60 -74 and 50-59 years at Increased Risk SUMMARY COMPARING MODELS FROM: GSK,Moderna AND University of Michigan -CDC Ismael R. Ortega -Sanchez, PhD NCIRD/CDC ACIP Meeting, June 26, 2024 1Disclaimer : The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. National Center for…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 114 pages
1 Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Evidence to Recommendations Framework (EtR): RSV Vaccination in Adults Aged 50 –59 years, 60 –74 years, and 75 years and older Amadea Britton, MD, Co -Lead Adult RSV…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 13 pages
1 Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. ACIP Adult RSV Work Group Clinical Considerations Respiratory Syncytial Virus (RSV) in Adults 60 and older Michael Melgar, MD Amadea Britton, MD Co-Leads, Adult RSV…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 6 pages
Introduction to Session: Combined Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B vaccine (Vaxelis) Jamie Loehr, MD Chair, ACIP Hib/Meningococcal Vaccines Work Group June 26, 2024National Center for Immunization & Respiratory Diseases 1 ACIP Meningococcal/Hib Vaccines Work Group ▪ ACIP Members on the WG •Jamie Loehr (Chair) •Wilbur Chen ▪ Ex Officio WG Members •Margaret Bash (FDA) •Matthew Clark (IHS)…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 53 pages
Evidence to Recommendations and Proposed Recommendations: Use of Vaxelis among American Indian and Alaska Native Infants Jennifer Collins, MD, MSc Co-Lead, ACIP Hib/Meningococcal Vaccines Work Group June 26, 2024National Center for Immunization & Respiratory Diseases 2▪Capsular polysaccharide (PRP) conjugated to carrier proteins –Tetanus toxoid (PRP -T) –Outer membrane protein of meningococcal serogroup B (PRP -OMP) ▪Highly immunogenic via activation of T -cell dependent immunity –95% of…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 18 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 10 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Adult Respiratory Syncytial Virus (RSV) Session Camille Kotton, MD Chair, Adult RSV Work Group Advisory Committee on Immunization Practices (ACIP) February 29, 2024 As a…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 48 pages
© 2024 Moderna, inc. All rights reserved.Overview of Moderna’s Investigational RSV Vaccine (mRNA-1345) in Adults ≥ 60 Years of Age Advisory Committee on Immunization Practices (ACIP) Rituparna Das, MD, PhD Feb 29, 2024The safety and efficacy of this investigational RSV vaccine have not been established in any country for any use Outline of PresentationOverview of mRNA- 1345, Moderna’s investigational RSV vaccine Pivotal Phase 2/3 trial Efficacy Safety Immunogenicity Persistence of…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 26 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Chronic Conditions as Risk Factors for RSV -Associated Hospitalization Rebecca C. Woodruff, PhD, MPH Epidemiologist, Centers for Disease Control and Prevention February…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 30 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases RSV Vaccination Implementation Update Carla Black, PhD Surveillance and Epidemiology Branch…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 34 pages
Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases Post -licensure safety monitoring of respiratory syncytial virus (RSV) vaccines in adults aged ≥60 years Tom Shimabukuro, MD, MPH, MBA On behalf of the Immunization Safety Office, CDC Advisory Committee on Immunization Practices (ACIP) February 29, 2024 Topics ▪Background ▪CDC vaccine safety monitoring for RSV vaccines in adults aged ≥60 years •V-safe •Vaccine Adverse Event Reporting…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 11 pages
1 Preliminary Analysis of Guillain-Barré Syndrome (GBS) following RSV Vaccination among adults 65 years and older Dr. Patricia Lloyd, ScM PhD Health Statistician Office of Biostatistics and Pharmacovigilance Center for Biologics Evaluation and Research U. S. Food & Drug Administration MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) Respiratory Syncytial Virus (RSV) Vaccines, Adults February 29, 2024 2 Outline •Study Methods •Statistical Analysis •Study Results…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 31 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. RSV Vaccination in Older Adults: Benefit -Risk Discussion Michael Melgar , MD Lauren Roper, MPH Advisory Committee on Immunization Practices February 29, 2024 There are…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 41 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. RSV Vaccination in Older Adults: Work Group Interpretations Amadea Britton, MD Advisory Committee on Immunization PracticesFebruary 29, 2024 2This includes follow- up of…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 6 pages
Introduction to Meningococcal Vaccines Session Jamie Loehr, MD ACIP Meningococcal Work Group Chair February 29, 2024National Center for Immunization & Respiratory Diseases The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. ▪Revisiting the adolescent meningococcal vaccine schedule –Does ACIP concur with the 4 options for further assessment? –What additional…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 24 pages
Revising the Adolescent Meningococcal Vaccine Schedule: Term of Reference and Considerations Sarah Schillie, MD, MPH, MBA February 29, 2024National Center for Immunization & Respiratory Diseases The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. ▪Vaccine recommendations and coverage ▪Epidemiology ▪Duration of vaccine -induced protection ▪Options for changing the…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 10 pages
GSK Pentavalent MenABCWY Vaccine: Term of Reference Sarah Schillie, MD, MPH, MBA February 29, 2024National Center for Immunization & Respiratory Diseases The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. ▪Two new MenABCWY vaccines: –Pfizer (“ Penbraya ,” ACIP voted October 2023) –GSK (clinical trials) ▪Each vaccine is a combination of an existing: –MenACWY …
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 12 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Pneumococcal Vaccines February 2024, ACIP Meeting February 29, 2024 Pneumococcal Vaccine Work Group ChairJames Loehr, MD, FAAFP ACIP Members Jamie Loehr (Chair, acting)…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 35 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Current Epidemiology of Pneumococcal Disease among Adults, United States February 2024, ACIP Meeting February 29, 2024 Ryan Gierke, MPH Outline Background on…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 14 pages
Public Interim Results from the PNEUMO Study . Pneumococcal pNeumonia Epidemiology, Urine serotyping, and Mental Outcomes study February 29, 2024 Study Leadership Wesley H. Self, MD Vanderbilt UniversityJ. Jackson Resser , MS Vanderbilt UniversityKelly D. Johnson, PhDMerck & Co., Inc. 1 Funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USANadine Rouphael , MD Emory University Public PNEUMO study overview •Adults 18+ years hospitalized with community acquired…